Search

Displaying results 5121 - 5130 of 6198 in total
  1. Drug

    NB-001

    go.drugbank.com/drugs/DB12716
    Investigational

    NB-001 has been investigated for the treatment of Recurrent Herpes Labialis.

  2. Drug

    Rheinanthrone

    go.drugbank.com/drugs/DB13175
    Experimental

    It is commonly produced by plants of the Rheum species [L772].

  3. Drug

    KP1237

    go.drugbank.com/drugs/DB18401
    Experimental

    KP1237 is a antibody-redirecting molecule composed of two binding sites (a CD38 binder and a universal antibody binding terminus binder) connected by a linker chain.

  4. Drug

    DAS-431 IV

    go.drugbank.com/drugs/DB05432
    Experimental

    DAS-431 IV is a dopamine D1 receptor agonist developed by DrugAbuse Sciences for the treatment of Addictions, Schizophrenia, Schizoaffective Disorders, Dementia, Parkinson's Disease, Strokes etc.

  5. Drug

    Sinecatechins

    go.drugbank.com/drugs/DB01266
    ApprovedInvestigationalNutraceutical

    Catechins constitute 85 to 95% (by weight) of the total drug substance which includes more than 55% of Epigallocatechin gallate (EGCg), other catechin derivatives such as Epicatechin (EC), Epigallocatechin

  6. Drug

    TC-2216

    go.drugbank.com/drugs/DB06044
    Investigational

    TC-2216 is an investigational novel small molecule that is being developed as an oral treatment for depression and anxiety disorders.

  7. Drug

    Chlorambucil

    go.drugbank.com/drugs/DB00291
    ApprovedInvestigational

    A nitrogen mustard alkylating agent used as antineoplastic agent for the treatment of various malignant and nonmalignant diseases. Although it is less toxic than most other nitrogen mustards, it has been listed as a known carcinogen in t...

  8. Drug

    Navitoclax

    go.drugbank.com/drugs/DB12340
    Investigational

    Navitoclax is an orally bioavailable small molecule inhibitor of Bcl-2 family proteins. It is a substance being studied in the treatment of lymphomas and other types of cancer.

  9. Drug

    QL1706

    go.drugbank.com/drugs/DB17562
    Investigational

    QL1706 is an investigational bifunctional antibody that combines the activity of both PD-1 and CTLA-4 antibodies.

  10. Drug

    OptPA

    go.drugbank.com/drugs/DB18325
    Experimental

    Optimized tPA (OptPA; W253R/R275S-tPA) is an engineered variant of tPA designed to exhibit reduced neurotoxicity.[A261486]